The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
A prostaglandins Falpha that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15. It is a naturally occurring prostaglandin used to induce labor.
[AKR1C3 protein results in increased reduction of Prostaglandin D2] which results in increased chemical synthesis of Dinoprost; [Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein results in increased metabolism of Prostaglandin D2] which results in increased abundance of Dinoprost]] which results in increased abundance of 15-deoxy-delta(12,14)-prostaglandin J2; Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein results in increased metabolism of Prostaglandin D2] which results in increased abundance of Dinoprost]
CAT protein inhibits the reaction [Dinoprost results in increased expression of PTGS2 mRNA]; CAT protein inhibits the reaction [Dinoprost results in increased localization of RELA protein]
Dinoprost results in decreased expression of CYP19A1 mRNA Dinoprost results in decreased expression of CYP19A1 mRNA; Dinoprost results in decreased expression of CYP19A1 protein Dinoprost promotes the reaction [GATA4 protein binds to CYP19A1 promoter]
[AL 8810 results in decreased activity of PTGFR protein] inhibits the reaction [[trans-10,cis-12-conjugated linoleic acid results in increased abundance of Dinoprost] which results in increased expression of EREG]; [trans-10,cis-12-conjugated linoleic acid promotes the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprost]] which results in increased expression of EREG; [trans-10,cis-12-conjugated linoleic acid results in increased abundance of Dinoprost] which results in increased expression of EREG Dinoprost results in increased expression of EREG
[Niacin results in decreased abundance of Dinoprost] which results in increased expression of FABP4 mRNA; [Niacin results in decreased abundance of Dinoprost] which results in increased expression of FABP4 protein
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Dinoprost affects the localization of FGF2 protein]; Cycloheximide inhibits the reaction [Dinoprost affects the localization of FGF2 protein]; Dinoprost affects the localization of [FGF2 protein binds to FGFR2 protein]; Dinoprost promotes the reaction [FGF2 protein binds to FGFR2 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [Dinoprost affects the localization of FGF2 protein]
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Dinoprost affects the localization of FGFR2 protein]; Dinoprost affects the localization of [FGF2 protein binds to FGFR2 protein]; Dinoprost promotes the reaction [FGF2 protein binds to FGFR2 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [Dinoprost affects the localization of FGFR2 protein] Dinoprost results in decreased expression of FGFR2 mRNA
IL1B protein results in increased abundance of Dinoprost Dexamethasone inhibits the reaction [IL1B protein results in increased abundance of Dinoprost]; IL10 protein inhibits the reaction [IL1B protein results in increased abundance of Dinoprost]; licochalcone A inhibits the reaction [IL1B protein results in increased abundance of Dinoprost]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [IL1B protein results in increased abundance of Dinoprost]
Dinoprost results in increased phosphorylation of MAP2K1 protein resveratrol inhibits the reaction [Dinoprost results in increased phosphorylation of MAP2K1 protein]; SRT1720 inhibits the reaction [Dinoprost results in increased phosphorylation of MAP2K1 protein]
Dinoprost results in increased phosphorylation of MAP2K2 protein Resveratrol inhibits the reaction [Dinoprost results in increased phosphorylation of MAP2K2 protein]; SRT1720 inhibits the reaction [Dinoprost results in increased phosphorylation of MAP2K2 protein]
Dinoprost affects the localization of MAPK1 protein resveratrol inhibits the reaction [Dinoprost results in increased phosphorylation of MAPK1 protein]; SRT1720 inhibits the reaction [Dinoprost results in increased phosphorylation of MAPK1 protein] 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Dinoprost results in increased phosphorylation of MAPK1 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Dinoprost results in increased activity of and results in increased phosphorylation of MAPK1 protein]; AG 1879 inhibits the reaction [Dinoprost results in increased phosphorylation of MAPK1 protein]; Dinoprost results in increased activity of and results in increased phosphorylation of MAPK1 protein; Egtazic Acid inhibits the reaction [Dinoprost results in increased phosphorylation of MAPK1 protein]; N-(8-aminooctyl)-5-iodonaphthalene-1-sulfonamide inhibits the reaction [Dinoprost results in increased activity of MAPK1 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [Dinoprost affects the localization of MAPK1 protein]; Trifluoperazine inhibits the reaction [Dinoprost results in increased activity of MAPK1 protein]; W 7 inhibits the reaction [Dinoprost results in increased activity of and results in increased phosphorylation of MAPK1 protein]
Dinoprost affects the localization of MAPK3 protein Dinoprost results in increased phosphorylation of MAPK3 protein resveratrol inhibits the reaction [Dinoprost results in increased phosphorylation of MAPK3 protein]; SRT1720 inhibits the reaction [Dinoprost results in increased phosphorylation of MAPK3 protein] 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Dinoprost results in increased phosphorylation of MAPK3 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Dinoprost results in increased activity of and results in increased phosphorylation of MAPK3 protein]; AG 1879 inhibits the reaction [Dinoprost results in increased phosphorylation of MAPK3 protein]; Dinoprost results in increased activity of and results in increased phosphorylation of MAPK3 protein; Egtazic Acid inhibits the reaction [Dinoprost results in increased phosphorylation of MAPK3 protein]; N-(8-aminooctyl)-5-iodonaphthalene-1-sulfonamide inhibits the reaction [Dinoprost results in increased activity of MAPK3 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [Dinoprost affects the localization of MAPK3 protein]; Trifluoperazine inhibits the reaction [Dinoprost results in increased activity of MAPK3 protein]; W 7 inhibits the reaction [Dinoprost results in increased activity of and results in increased phosphorylation of MAPK3 protein]
Dinoprost results in increased phosphorylation of MAPK8 protein resveratrol inhibits the reaction [Dinoprost results in increased phosphorylation of MAPK8 protein]; SRT1720 inhibits the reaction [Dinoprost results in increased phosphorylation of MAPK8 protein]
Dinoprost results in increased phosphorylation of MAPK9 protein resveratrol inhibits the reaction [Dinoprost results in increased phosphorylation of MAPK9 protein]; SRT1720 inhibits the reaction [Dinoprost results in increased phosphorylation of MAPK9 protein]
[Niacin results in decreased abundance of Dinoprost] which results in increased expression of PPARG mRNA; [Niacin results in decreased abundance of Dinoprost] which results in increased expression of PPARG protein
Dinoprost results in increased expression of PTGFR mRNA [AL 8810 results in decreased activity of PTGFR protein] inhibits the reaction [[trans-10,cis-12-conjugated linoleic acid results in increased abundance of Dinoprost] which results in increased expression of EREG]
[Celecoxib results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprost; [meloxicam results in decreased activity of PTGS2 protein] inhibits the reaction [trans-10,cis-12-conjugated linoleic acid results in increased chemical synthesis of Dinoprost]; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [trans-10,cis-12-conjugated linoleic acid results in increased chemical synthesis of Dinoprost]; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprost; [Niacin results in decreased expression of PTGS2 mRNA] which results in decreased abundance of Dinoprost; [PTGS2 gene mutant form results in increased susceptibility to Kainic Acid] which results in increased abundance of Dinoprost; [trans-10,cis-12-conjugated linoleic acid promotes the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprost]] which results in increased expression of EREG PTGS2 protein results in increased abundance of Dinoprost Dinoprost results in increased expression of PTGS2 mRNA [Linoleic Acids, Conjugated results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprost; [Lipopolysaccharides results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Dinoprost; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [CGB3 protein results in increased chemical synthesis of Dinoprost]; resveratrol inhibits the reaction [[Linoleic Acids, Conjugated results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprost]; resveratrol inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Dinoprost]; SIRT1 protein promotes the reaction [resveratrol inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Dinoprost]] [Dinoprost results in increased expression of PTGS2 mRNA] which results in increased abundance of Dinoprost; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprost; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased secretion of Dinoprost; CAT protein inhibits the reaction [Dinoprost results in increased expression of PTGS2 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [PTGS2 protein results in increased abundance of Dinoprost]
Dinoprost results in increased expression of RAF1 protein modified form resveratrol inhibits the reaction [Dinoprost results in increased expression of RAF1 protein modified form]; SRT1720 inhibits the reaction [Dinoprost results in increased expression of RAF1 protein modified form]
CAT protein inhibits the reaction [Dinoprost results in increased localization of RELA protein]; Dinoprost results in increased localization of and results in increased activity of RELA protein
SIRT1 protein promotes the reaction [resveratrol inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Dinoprost]]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Dinoprost results in increased expression of and results in increased secretion of TNFRSF11B protein]; Dinoprost results in increased expression of and results in increased secretion of TNFRSF11B protein; pyrazolanthrone inhibits the reaction [Dinoprost results in increased expression of and results in increased secretion of TNFRSF11B protein]; resveratrol inhibits the reaction [Dinoprost results in increased expression of and results in increased secretion of TNFRSF11B protein]; resveratrol inhibits the reaction [Dinoprost results in increased expression of TNFRSF11B mRNA]; SB 203580 inhibits the reaction [Dinoprost results in increased expression of and results in increased secretion of TNFRSF11B protein]; SRT1720 inhibits the reaction [Dinoprost results in increased expression of and results in increased secretion of TNFRSF11B protein]
PTGR1 protein results in increased abundance of 15-keto-13,14-dihydroprostaglandin F2alpha [PTGR1 protein results in increased metabolism of 15-ketoprostaglandin F2alpha] which results in increased abundance of 15-keto-13,14-dihydroprostaglandin F2alpha
PTGR1 protein results in increased metabolism of 15-ketoprostaglandin F2alpha [PTGR1 protein results in increased metabolism of 15-ketoprostaglandin F2alpha] which results in increased abundance of 15-keto-13,14-dihydroprostaglandin F2alpha
[Lead co-treated with APP protein modified form] results in increased abundance of 8-epi-prostaglandin F2alpha APP protein modified form results in increased abundance of 8-epi-prostaglandin F2alpha
1-((4-methylsulfonyl)phenyl)-3-trifluoromethyl-5-(4-fluorophenyl)pyrazole inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; Ascorbic Acid inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; Ascorbic Acid promotes the reaction [Aspirin inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]]; Aspirin inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; Dehydroascorbic Acid inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; Indomethacin inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; resveratrol inhibits the reaction [IL1B protein results in increased abundance of 8-epi-prostaglandin F2alpha] pyrrolidine dithiocarbamic acid inhibits the reaction [IL1B protein results in increased abundance of 8-epi-prostaglandin F2alpha]; Rotenone inhibits the reaction [IL1B protein results in increased abundance of 8-epi-prostaglandin F2alpha]
PAFAH2 protein affects the metabolism of 8-epi-prostaglandin F2alpha PAFAH2 protein affects the reaction [Carbon Tetrachloride results in increased abundance of 8-epi-prostaglandin F2alpha]
[L 745337 results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of 8-epi-prostaglandin F2alpha; [lipopolysaccharide, E. coli O26-B6 results in increased expression of PTGS2 protein] which results in increased chemical synthesis of 8-epi-prostaglandin F2alpha; [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] which results in increased chemical synthesis of 8-epi-prostaglandin F2alpha
8-epi-prostaglandin F2alpha binds to and results in increased activity of TBXA2R protein TBXA2R protein affects the susceptibility to 8-epi-prostaglandin F2alpha